These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20809091)

  • 1. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.
    Botteman MF; Meijboom M; Foley I; Stephens JM; Chen YM; Kaura S
    Eur J Health Econ; 2011 Dec; 12(6):575-88. PubMed ID: 20809091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands.
    Carter JA; Joshi A; Kaura S; Botteman MF
    J Med Econ; 2011; 14(3):288-98. PubMed ID: 21469915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
    Carter JA; Joshi AD; Kaura S; Botteman MF
    Pharmacoeconomics; 2012 May; 30(5):373-86. PubMed ID: 22500986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
    Joshi AD; Carter JA; Botteman MF; Kaura S
    Clin Ther; 2011 Mar; 33(3):291-304.e8. PubMed ID: 21600384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
    Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.
    Delea TE; Rotter J; Taylor M; Chandiwana D; Bains M; El Ouagari K; Kaura S; Morgan GJ
    J Med Econ; 2012; 15(3):454-64. PubMed ID: 22316275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
    Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G
    J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
    Snedecor SJ; Carter JA; Kaura S; Botteman MF
    Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
    Snedecor SJ; Carter JA; Kaura S; Botteman MF
    J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
    Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
    Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
    Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
    Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
    Cristino J; Finek J; Jandova P; Kolek M; Pásztor B; Giannopoulou C; Qian Y; Brezina T; Lothgren M
    J Med Econ; 2017 Aug; 20(8):799-812. PubMed ID: 28485692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.
    Yasuda Y; Fujii Y; Yuasa T; Kitsukawa S; Urakami S; Yamamoto S; Yonese J; Takahashi S; Fukui I
    Int J Clin Oncol; 2013 Oct; 18(5):877-83. PubMed ID: 22965827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
    Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
    J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
    Shapiro CL; Moriarty JP; Dusetzina S; Himelstein AL; Foster JC; Grubbs SS; Novotny PJ; Borah BJ
    J Clin Oncol; 2017 Dec; 35(35):3949-3955. PubMed ID: 29023215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
    Saad F; Segal S; Eastham J
    Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.